Integrated Diagnostics (IDHC) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
28 Apr, 2026Executive summary
Achieved 37% year-over-year revenue growth in FY 2025, reaching EGP 7.9 billion, with strong expansion across Egypt, Jordan, Nigeria, and Saudi Arabia, and progress on strategic priorities including network expansion, service diversification, and digitalization.
Adjusted net profit rose 79% year-over-year to EGP 1,262 million, with margin expansion at all profitability levels and sustained improvements in scalability.
Test volumes increased 11% year-over-year to 43.5 million, and average revenue per test rose 24%.
Strategic price increases and cost optimization drove margin improvements, supported by easing inflation and currency stabilization in key markets.
Strengthened leadership in Egypt and Jordan, with encouraging progress in Nigeria and Saudi Arabia.
Financial highlights
Revenue grew 37% year-over-year to EGP 7.9 billion, driven by both volume (+11%) and value (+24% average revenue per test).
EBITDA margin expanded to 35% from 30% last year; gross profit margin rose to 43% from 38%.
Adjusted net profit increased 79% year-over-year to EGP 1,262 million; reported net profit reached EGP 1.3 billion, up 29%.
Board declared a dividend of $0.0085 per share, totaling $4.9 million.
FY 2025 CAPEX totaled EGP 790 million (10% of revenue), including expansion and acquisitions.
Outlook and guidance
FY 2026 consolidated revenue expected to grow 39% year-over-year; guidance targets 25% sales growth, with 10% from price increases and 15% from volume; EBITDA margin expected at 33%-34%.
Targeting 200 new branch openings in 2026 across Egypt, Saudi Arabia, and Jordan, including clinics and hospitals.
Saudi Arabia revenue target for 2026 is SAR 18 million; EBITDA break-even expected by 2028.
CapEx forecast for 2026 is 5.9% of total sales, mainly allocated to Egypt.
Focus remains on Saudi Arabia ramp-up, volume growth in Jordan and Nigeria, and continued margin improvement through digitalization and cost management.
Latest events from Integrated Diagnostics
- Q1 revenue up 28% and net profit up 139%, with 2024 guidance for 30% growth and margin gains.IDHC
Q1 2024 TU31 Jan 2026 - 33% revenue and 127% net profit growth, with margin expansion and strong Egypt performance.IDHC
H1 202422 Jan 2026 - Net profit up 87% on 34% revenue growth, with margin expansion and network growth.IDHC
Q3 2024 TU13 Jan 2026 - 41% revenue growth and margin expansion highlight robust 2025 performance and outlook.IDHC
Q3 2025 TU9 Dec 2025 - Record revenue, margin gains, and Saudi expansion drive strong outlook; dividend deferred.IDHC
H2 202428 Nov 2025 - Q1 2025 delivered 35% revenue growth, margin expansion, and doubled adjusted net profit.IDHC
Q1 2025 TU26 Nov 2025 - Revenue up 42% and adjusted EBITDA up 78% in H1 2025, with strong margin expansion.IDHC
H1 202515 Sep 2025